ABO incompatible living renal transplantation with a steroid sparing protocol

Transplantation

Volumn 86, Issue 7, 2008, Pages 901-906

  Galliford, Jack ^a   Charif, Rawya ^a   Chan, Ka Kit ^a   Loucaidou, Marina ^a   Cairns, Tom ^a   Cook, H Terence ^a   Dorling, Anthony ^a   Hakim, Nadey ^a   McLean, Adam ^a   Papalois, Vassilios ^a   Malde, Ranjan ^b   Regan, Fiona ^a,b   Redman, Martin ^b   Warrens, Anthony N ^a   Taube, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

ABO incompatible; Renal transplantation; Steroid sparing

Indexed keywords

DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; CORTICOSTEROID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; ORGAN DONOR; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; DRUG ADMINISTRATION; DRUG COMBINATION; IMMUNOLOGY; LIVING DONOR; MIDDLE AGED; PATIENT SELECTION;

ABO BLOOD-GROUP SYSTEM; ADRENAL CORTEX HORMONES; ADULT; BLOOD GROUP INCOMPATIBILITY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT SELECTION; PREDNISOLONE; TACROLIMUS;

EID: 56049125713     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181880c0f     Document Type: Article

References (19)

1. Takahashi K,Saito K,TakaharaS, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089.
2. Ishida H, Miyamoto N, Shirakawa H, et al. Evaluation of immunosuppres-sive regimens in ABO-incompatible living kidney transplantation - Single center analysis. Am J Transplant 2007; 7: 825.
3. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145.
4. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75: 971.
5. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis CMV hyperimune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
6. Segev DL, Simpkins CE, WarrenDS,et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5: 2570.
7. Cittero F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001; 72(12 suppl): S75.
8. Woodle ES; for the Fujisawa Corticosteroid Withdrawal Study Group. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of cor-ticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: One year report. Transplant Proc 2005; 37: 804.
9. Borrows R, Chan K, Loucaidou M, et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 2006; 81: 125.
10. Borrows R, Loucaidou M, van Tromp J, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004; 4: 1845.
11. Khwaja K, Asolati M, Harmon JV, et al. Outcome at 3 years with a prednisone-free maintenance regimen:Asingle-centre experience with 349 kidney transplant recipients. Am J Transplant 2004; 4: 980.
12. Kaufmann DB, Leventhal JR, AxelrodD,et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - Long term results. Am J Transplant 2005; 5: 2539.
13. RedmanM,Malde R,ContrerasM.Comparison ofIgM and IgG anti-A and anti-B levels in Asian, Caucasian and Negro donors in the North West Thames region. Vox Sang 1990; 59: 89.
14. Solez K, Colvin RB, Racusen LC, et al. Banff'05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
15. Cockcroft D, Gault MD. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
16. Levey AS, Bosch JP, Lewis JB, et al.A more accurate methodto estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
17. Gloor JM, Lager DJ, Fidler ME, et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 1572.
18. Shimmura H, Tanabe K, Ishikawa N, et al. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Trans plantation 2000; 70: 1331.
19. Ramsey G. Red cell antibodies arising from solid organ transplants. Transfusion 1991; 31: 77.